GlassScriptPhysician profile
Jason F White
NPI 1992758270
$2,444.51
in general payments reported to CMS, 2019-2025
24 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $117 · 2022: $95.67 · 2023: $492 · 2024: $702 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $612.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $267.00 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Madrigal Pharmaceuticals | $231.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $196.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $134.47 | 2019-2024 | Verquvo, Gardasil, Gardasil 9 |
| Amgen INC. | $127.72 | 2023-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $84.34 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $81.17 | 2019-2025 | Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $75.12 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $72.57 | 2024-2025 | Voquezna |
| Dexcom, INC. | $59.21 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $50.03 | 2023-2025 | |
| Exact Sciences Corporation | $48.16 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $48.06 | 2023-2024 | Rexulti |
| Abbott Laboratories | $47.81 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $45.41 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $45.41 | 2019-2023 | |
| Verona Pharma, INC. | $45.38 | 2025 | Ohtuvayre |
| Baxter Healthcare | $44.71 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $40.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.33 | 2023-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.46 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $16.81 | 2019 | |
| Shield Therapeutics INC | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.